证券日报网讯 8月22日晚间，宣泰医药发布关于2025年半年度利润分配方案的公告称，公司拟向全体股 东每10股派发现金红利0.25元（含税）。截至本公告披露日，公司总股本为453，340，000股，扣减回 购专用证券账户中股份总数4，336，109股后的股本为449，003，891股，以此计算拟派发现金红利合计 11，225，097.28元（含税）。本次公司现金分红占2025年1月—6月份归属于母公司股东的净利润比例 为24.62%。 （文章来源：证券日报） ...

Core Viewpoint - Next week, 31 stocks will have their restrictions lifted, with a total market value of 23.481 billion yuan based on the latest closing prices [1] Group 1: Stock Unlocking Details - Rongbai Technology will have 250 million shares listed for circulation, primarily consisting of original shareholders' restricted shares, with a market value of 5.707 billion yuan [1] - Zhenhua Wind Power follows with 86 million shares to be unlocked, also mainly original shareholders' restricted shares, amounting to a market value of 5.282 billion yuan [1] Group 2: Unlocking Ratios - Xuantai Pharmaceutical has the highest unlocking ratio at 68.61%, with Zhenhua Wind Power, Rongbai Technology, and Kaige Precision Machinery also showing significant unlocking ratios [1]

Group 1 - The company reported a revenue of 220 million yuan and a net profit of 45.5857 million yuan for the first half of 2025, with a proposed cash dividend of 0.25 yuan per 10 shares, totaling 11.2251 million yuan, which accounts for 24.62% of the net profit [1] - The company has implemented a strategy focusing on "first generics and high activity," expanding its product pipeline across various therapeutic areas, including antifungal, psychiatric, diabetes, cancer, digestive, hypertension, kidney, and pain management [1] - The company has received approval for 16 products, including several first generics in China and the U.S., establishing market barriers and enhancing product competitiveness [1] Group 2 - In the CRO/CMO sector, the company has deepened collaborations with domestic and international innovative pharmaceutical companies, adding 8 new clients and advancing 11 innovative drug formulation developments [2] - The company has successfully facilitated the market approval of two innovative drugs and has completed over 100 innovative drug formulation developments for global clients, with 8 new drugs approved for commercialization [2] - The company aims to leverage its dual registration capabilities and GMP production base to enhance collaborations with leading innovative pharmaceutical companies and foster new business growth [2] Group 3 - The company maintains a rigorous quality management system, ensuring compliance with international standards and enhancing product quality [3] - The company has successfully passed 12 audits from domestic and international drug regulatory agencies this year, including first-time approvals from the Saudi FDA and EMA [3] - The company plans to continue its dual strategy of innovation-driven and international expansion, aiming to enhance its core competitiveness and global influence in the pharmaceutical industry [3]

Core Viewpoint - Xuantai Pharmaceutical (688247) reported a slight increase in revenue and net profit for the first half of 2025, reflecting confidence in future growth and commitment to shareholder interests through a shareholding pledge by the controlling shareholder [1][2]. Financial Performance - The company achieved operating revenue of 220 million yuan, a year-on-year increase of 0.74% [1]. - The net profit attributable to shareholders was 45.5857 million yuan, with a non-recurring net profit of 39.5230 million yuan [1]. Regulatory Compliance and Certifications - Xuantai Pharmaceutical's solid tablet workshop received GMP certification from the EU EMA in July 2025, adding to its existing certifications from major global regulatory bodies including NMPA, FDA, PMDA, and SFDA [2]. - The company successfully passed 12 audits from domestic and international drug regulatory agencies this year, enhancing its compliance and operational capabilities [1][2]. Production Capacity and Quality Management - The company operates over 16,000 square meters of high-standard production facilities, with upgraded production lines improving efficiency and capacity for various products [2]. - A rigorous quality management system has strengthened the company's competitiveness in the global market [2]. Product Development and Market Expansion - Xuantai Pharmaceutical has 16 approved products across various therapeutic areas, including antifungal, psychiatric, diabetes, cancer, digestive, hypertension, renal, and analgesic treatments, with several first-to-market products [3]. - The company is advancing its pipeline with innovative drug formulations and has received temporary FDA approval for products like Enzalutamide and Dapagliflozin Metformin Extended-Release Tablets [2][3]. Strategic Initiatives and Future Outlook - The company is focused on innovation-driven and international expansion strategies, aiming to enhance product commercialization and strengthen formulation technology research [3]. - Xuantai Pharmaceutical plans to increase its global influence and competitiveness, aspiring to become a leading global pharmaceutical enterprise [3].

8月22日宣泰医药发布2025半年度分配预案，拟10派0.25元（含税），预计派现金额合计为1122.51万 元。派现额占净利润比例为24.62%，这是公司上市以来，累计第5次派现。 证券时报·数据宝统计显示，公司今日公布了半年报，共实现营业收入2.20亿元，同比增长0.74%，实现 净利润4558.57万元，同比下降15.82%，基本每股收益为0.1元，加权平均净资产收益率为3.53%。 资金面上看，该股今日主力资金净流出144.94万元，近5日主力资金净流出2338.17万元。 两融数据显示，该股最新融资余额为8232.34万元，近5日减少203.19万元，降幅为2.41%。 按申万行业统计，宣泰医药所属的医药生物行业共有24家公司公布了2025半年度分配方案，派现金额最 多的是药明康德，派现金额为10.03亿元，其次是东阿阿胶、华润三九，派现金额分别为8.17亿元、7.51 亿元。（数据宝） 公司上市以来历次分配方案一览 | 日期 | 分配方案 | 派现金额合计（亿元） | 股息率（%） | | --- | --- | --- | --- | | 2025.06.30 | 10派0.25元（含税） | ...

Group 1 - Gujia Home achieved a net profit of 1.02 billion yuan in the first half of 2025, a year-on-year increase of 13.89% [1] - Gujia Home's revenue for the first half of 2025 was 9.80 billion yuan, up 10.02% year-on-year [1] - Phoenix Holdings reported a net profit of 11.04 million yuan, successfully turning a profit [1] - Phoenix Holdings' revenue increased by 200.78% year-on-year to 291 million yuan [1] - Zheshang Securities recorded a net profit of 1.15 billion yuan, a year-on-year growth of 46.49% [1] - Zheshang Securities' revenue decreased by 23.66% to 6.11 billion yuan [1] Group 2 - Tianjin Port's net profit was 503 million yuan, a year-on-year decrease of 18.33% [3] - Tianjin Port's revenue for the first half of 2025 was 6.18 billion yuan, an increase of 4.33% year-on-year [3] - Xuantai Pharmaceutical reported a net profit of 45.59 million yuan, down 15.82% year-on-year [5] - Xuantai Pharmaceutical's revenue was 220 million yuan, a slight increase of 0.74% year-on-year [5] Group 3 - Yilida achieved a net profit of 40.03 million yuan, a year-on-year increase of 18.32% [7] - Yilida's revenue for the first half of 2025 was 758 million yuan, up 12.56% year-on-year [7] - Zhongji United reported a net profit of 262 million yuan, a significant year-on-year increase of 86.61% [9] - Zhongji United's revenue was 818 million yuan, a year-on-year growth of 43.52% [9] Group 4 - China Shipbuilding Special Gas reported a net profit of 178 million yuan, a slight decrease of 0.55% year-on-year [10] - China Shipbuilding Special Gas' revenue was 1.04 billion yuan, an increase of 12.60% year-on-year [10] - Xinyuan Intelligent Manufacturing achieved a net profit of 9.79 million yuan, a year-on-year increase of 284.45% [11] - Xinyuan Intelligent Manufacturing's revenue was 329 million yuan, up 388.33% year-on-year [11] Group 5 - Jiudian Pharmaceutical reported a net profit of 291 million yuan, a year-on-year increase of 2.57% [13] - Jiudian Pharmaceutical's revenue was 1.51 billion yuan, a year-on-year growth of 10.67% [13] - Boya Biological reported a net profit of 225 million yuan, down 28.68% year-on-year [15] - Boya Biological's revenue was 1.01 billion yuan, an increase of 12.51% year-on-year [15] Group 6 - True Love Home achieved a net profit of 197 million yuan, a year-on-year increase of 484.48% [17] - True Love Home's revenue was 390 million yuan, up 21.82% year-on-year [17] - Dongfang Electronics reported a net profit of 302 million yuan, a year-on-year increase of 19.65% [19] - Dongfang Electronics' revenue was 3.16 billion yuan, a year-on-year growth of 12.18% [19] Group 7 - Watte Holdings achieved a net profit of 18.41 million yuan, a year-on-year increase of 23.94% [21] - Watte Holdings' revenue was 906 million yuan, up 12.29% year-on-year [21] - Tianqin Equipment reported a net profit of 16.36 million yuan, a year-on-year increase of 2.78% [22] - Tianqin Equipment's revenue was 111 million yuan, a year-on-year growth of 18.42% [22] Group 8 - Yingfeng Environment achieved a net profit of 382 million yuan, a year-on-year increase of 0.43% [24] - Yingfeng Environment's revenue was 6.46 billion yuan, up 3.69% year-on-year [24] - Kexin Machinery reported a net profit of 52.20 million yuan, a year-on-year decrease of 46.18% [26] - Kexin Machinery's revenue was 592 million yuan, down 17.26% year-on-year [26] Group 9 - Tengda Construction reported a net profit of 108 million yuan, a year-on-year decrease of 0.69% [27] - Tengda Construction's revenue was 1.61 billion yuan, down 5.20% year-on-year [27] - Canaan Technology achieved a net profit of 7.35 million yuan, a year-on-year decrease of 38.46% [29] - Canaan Technology's revenue was 560 million yuan, up 1.29% year-on-year [29] Group 10 - Metro Design reported a net profit of 221 million yuan, a year-on-year increase of 6.58% [30] - Metro Design's revenue was 1.32 billion yuan, up 5.31% year-on-year [30] - China Shipbuilding Special Gas plans to use up to 2.9 billion yuan of idle funds for cash management [31] - The company intends to invest in safe, liquid, principal-protected products [31] Group 11 - Jiuchuang Biotechnology received a medical device registration certificate for its lupus anticoagulant detection kit [32] - The product is intended for in vitro qualitative detection of lupus anticoagulant in human plasma [32] - Xinowei's subsidiary received approval for clinical trials of its innovative drug [33] - The drug is a humanized monoclonal antibody intended for treating multiple cancers [33] Group 12 - Dongcheng Pharmaceutical's subsidiary received FDA approval for clinical trials of its targeted radiopharmaceutical [34] - The drug is intended for treating advanced prostate cancer [34] - Shandong Road and Bridge received approval to issue bonds up to 4 billion yuan [35] - The company specializes in road and bridge engineering construction [35] Group 13 - Diou Home plans to invest 500 million yuan to establish a subsidiary focused on generative AI [36] - The investment aims to transform the company into a full-stack industrial intelligent service provider [36] - Dayilong achieved a net profit of 90.87 million yuan, a year-on-year increase of 217.89% [37] - Dayilong's revenue was 957 million yuan, up 57.35% year-on-year [37] Group 14 - Chaohongji reported a net profit of 331 million yuan, a year-on-year increase of 44.34% [38] - Chaohongji's revenue was 4.10 billion yuan, up 19.54% year-on-year [38] - Taiji Group reported a net profit of 139 million yuan, a year-on-year decrease of 71.94% [39] - Taiji Group's revenue was 5.66 billion yuan, down 27.63% year-on-year [39] Group 15 - Suneng Co. reported a net profit of 93.19 million yuan, a year-on-year decrease of 90.13% [41] - Suneng Co.'s revenue was 5.57 billion yuan, down 17.15% year-on-year [41] - Three Gorges Water Conservancy reported a net profit of 47.93 million yuan, a year-on-year decrease of 79.07% [42] - Three Gorges Water Conservancy's revenue was 4.90 billion yuan, down 6.10% year-on-year [42] Group 16 - Furida reported a net profit of 108 million yuan, a year-on-year decrease of 15.16% [44] - Furida's revenue was 1.79 billion yuan, down 7.05% year-on-year [44] - Chenzhou Electric International achieved a net profit of 25.92 million yuan, a year-on-year increase of 29.55% [46] - Chenzhou Electric International's revenue was 1.96 billion yuan, up 1.26% year-on-year [46] Group 17 - Farlantek achieved a net profit of 122 million yuan, a year-on-year increase of 41.05% [47] - Farlantek's revenue was 1.18 billion yuan, up 46.63% year-on-year [47] - Huitai Medical reported a net profit of 425 million yuan, a year-on-year increase of 24.11% [48] - Huitai Medical's revenue was 1.21 billion yuan, up 21.26% year-on-year [48] Group 18 - Dameng Data's director is under investigation for suspected violations [49] - The company's daily operations remain normal [49] - Maiwei Co. reported a net profit of 394 million yuan, a year-on-year decrease of 14.59% [50] - Maiwei Co.'s revenue was 4.21 billion yuan, down 13.48% year-on-year [50] Group 19 - Waiservice Holdings achieved a net profit of 384 million yuan, a year-on-year increase of 5.51% [52] - Waiservice Holdings' revenue was 12.25 billion yuan, up 16.15% year-on-year [52] - Huakang Co. reported a net profit of 134 million yuan, a year-on-year decrease of 3.38% [53] - Huakang Co.'s revenue was 1.87 billion yuan, up 37.32% year-on-year [53] Group 20 - Bluelight Optical achieved a net profit of 103 million yuan, a year-on-year increase of 110.27% [54] - Bluelight Optical's revenue was 577 million yuan, up 52.54% year-on-year [54] - Shunwang Technology reported a net profit of 162 million yuan, a year-on-year increase of 69.22% [55] - Shunwang Technology's revenue was 1.01 billion yuan, up 25.09% year-on-year [55] Group 21 - Anbiping reported a net loss of 12.50 million yuan in the first half of 2025 [56] - Anbiping's revenue was 159 million yuan, down 30.11% year-on-year [56] - Jinhua Co. reported a net profit of 6.20 million yuan, a year-on-year decrease of 34.53% [57] - Jinhua Co.'s revenue was 241 million yuan, down 1.90% year-on-year [57] Group 22 - Xiehe Electronics achieved a net profit of 28.96 million yuan, a year-on-year decrease of 8.31% [59] - Xiehe Electronics' revenue was 451 million yuan, up 12.13% year-on-year [59] - Huguang Co. reported a net profit of 276 million yuan, a year-on-year increase of 8.40% [60] - Huguang Co.'s revenue was 3.63 billion yuan, up 6.20% year-on-year [60]

（文章来源：每日经济新闻） 宣泰医药8月22日晚间发布半年度业绩报告称，2025年上半年营业收入约2.2亿元，同比增加0.74%；归 属于上市公司股东的净利润约4559万元，同比减少15.82%；基本每股收益0.1元，同比减少16.67%。 ...

上海宣泰医药科技股份有限公司 信息披露暂缓与豁免管理制度 第一章 总则 第二章 暂缓、豁免披露信息的范围 1 第一条 为规范上海宣泰医药科技股份有限公司（以下简称"公司"）的信 息披露暂缓与豁免行为，促进公司依法规范运作，维护公司及投资 者的合法权益，依据《中华人民共和国证券法》《上市公司信息披 露管理办法》《上市公司信息披露暂缓与豁免管理规定》《上海证券 交易所科创板股票上市规则》（以下简称"《上市规则》"）和《上海 证券交易所科创板上市公司自律监管指引第 1 号——规范运作 （2025 年 5 月修订）》等法律、法规、规范性文件及《上海宣泰医 药科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定， 制定本制度。 第二条 公司和其他信息披露义务人按照《上市规则》及上海证券交易所（以 下简称"上交所"）其他相关业务规则的规定，暂缓、豁免披露临 时报告，在定期报告、临时报告中豁免披露中国证券监督管理委员 会和上交所规定或者要求披露的内容，适用本制度。 第三条 公司和其他信息披露义务人应当审慎确定信息披露暂缓、豁免事项， 履行内部审核程序后实施，并接受上交所对有关信息披露暂缓、豁 免事项的事后监管。 第 ...

Core Insights - The company reported a revenue of 220 million yuan for the first half of 2025, reflecting a year-on-year growth of 0.74% [1] - The net profit attributable to shareholders decreased by 15.82% to 45.5857 million yuan, with basic earnings per share at 0.1 yuan [1] - The company plans to distribute a cash dividend of 0.25 yuan per 10 shares (tax included) to all shareholders [1] Revenue and Profit Analysis - The significant decline in sales revenue for the product Posaconazole enteric-coated tablets was attributed to its failure to win a bid in the 10th batch of centralized procurement scheduled for December 2024, leading to a 73.09% decrease in domestic sales revenue and a 28.54 percentage point drop in gross margin [1] - Sales revenue and profit-sharing income for Mesalazine enteric-coated tablets in the U.S. market fell by 58.36% and 19.90% respectively, due to increased competition from approved generic manufacturers and rising tariffs [1]

格隆汇8月22日丨宣泰医药(688247.SH)公布2025年半年度报告，上半年实现营业收入2.2亿元，同比增长 0.74%；归属于上市公司股东的净利润4558.57万元，同比下降15.82%；归属于上市公司股东的扣除非经 常性损益的净利润3952.3万元，同比下降19.00%；基本每股收益0.10元。公司拟向全体股东每10股派发 现金红利0.25元（含税）。 ...